Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
批准号:
10617954
负责人:
Karen J Wernli
金额:
$200.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-30 至 2027-09-29
中文摘要
摘要
英文摘要
ABSTRACT
As one of the current US Influenza Vaccine Effectiveness (US Flu VE) Network sites, we propose continuing
our studies of vaccine effectiveness (VE) for seasonal influenza, COVID-19, and other respiratory viruses to
prevent acute respiratory illness (ARI) in Washington state from 2022 to 2027 (Component A). Since March
2020, the COVID-19 pandemic has resulted in >80 million infections and ~1 million US deaths. Until the
pandemic, the dominant respiratory virus impacting public health seasonally was influenza. In the US, up to 5%
of the population sought outpatient care during a severe epidemic, and a typical epidemic caused tens of
thousands of deaths and hundreds of thousands of hospitalizations. The COVID-19 pandemic catalyzed rapid
adoption of telehealth care, in particular for patients with mild to moderate ARI, shifting patients from
ambulatory visits to minimize healthcare exposure to COVID-19. Currently, influenza and COVID-19
vaccinations are the best available tools for reducing the respiratory virus burden and maintaining population
immunity. Vaccination programs represent a substantial public health investment. Given the magnitude of this
investment and the dynamic impact of respiratory viruses on public health, policymakers need accurate, timely,
and relevant data representing real-world VE to monitor the impact on respiratory illness burden in US
populations. The next 5 years of surveillance of respiratory illness in US populations will be critical in
accounting for changes in respiratory virus burden. The US Flu VE Network has the capacity, infrastructure,
research methods, and specimen collection experience to monitor any respiratory virus within US health care.
From 2022-2027, we propose to enroll ~6000 KPWA infants, children, and adults including older adults in
urgent care clinics, collect respiratory and blood specimens, complete enrollment and post-enrollment
questionnaires, collaborate with laboratory services to type and genetically sequence specimens, collate and
curate EHR data, collaborate across the Network with Component A sites, share data with Network
Coordination Center (Component B), share specimens with site leading Component E, participate in Network
research activities including dissemination, and develop new methods for estimation and inference in VE. Our
specific aims to meet the goals of the US Flu VE Network are: Aim 1. Establish a platform to estimate VE of
seasonal influenza and COVID-19 vaccines against respiratory viral illnesses in preventing laboratory-
confirmed illness among children and adults with mild or moderate illness seeking care in ambulatory settings
(Objective 1); Aim 2. Establish a protocol to obtain influenza and SARS-CoV-2 viral sequences from
specimens collected among infected participants in the proposed outpatient network (Objective 2); Aim 3.
Describe capacity and diagnostic test methods available in KPWA and methods to obtain COVID-19
vaccination data outside influenza season (Objective 3). Aim 4. Improve precision of the test-negative design
by incorporate two-phase sampling methodology (methods aim).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
-
批准号:10698201
-
项目类别:
-
资助金额:$140.0万
-
财政年份:2022
-
负责人:Karen J Wernli
-
依托单位:
Multilevel Interventions to Increase Adherence to Lung Cancer Screening
-
批准号:10274176
-
项目类别:
-
资助金额:$71.22万
-
财政年份:2021
-
负责人:Karen J Wernli
-
依托单位:
Multilevel Interventions to Increase Adherence to Lung Cancer Screening
-
批准号:10662255
-
项目类别:
-
资助金额:$64.1万
-
财政年份:2021
-
负责人:Karen J Wernli
-
依托单位:
Patient Provider Communication Larch Supplement
-
批准号:10830643
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2021
-
负责人:Karen J Wernli
-
依托单位:
Multilevel Interventions to Increase Adherence to Lung Cancer Screening
-
批准号:10449314
-
项目类别:
-
资助金额:$65.97万
-
财政年份:2021
-
负责人:Karen J Wernli
-
依托单位:
National trends in end of life care for adolescent and young adult cancer patients
-
批准号:9099278
-
项目类别:
-
资助金额:$25.62万
-
财政年份:2016
-
负责人:Karen J Wernli
-
依托单位:
Mammographic Breast Density and Ovarian Cancer
-
批准号:8106615
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2011
-
负责人:Karen J Wernli
-
依托单位:
Comparative effectiveness of colorectal cancer screening
-
批准号:8555316
-
项目类别:
-
资助金额:$6.34万
-
财政年份:2011
-
负责人:Karen J Wernli
-
依托单位:
Mammographic Breast Density and Ovarian Cancer
-
批准号:8235838
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2011
-
负责人:Karen J Wernli
-
依托单位:
Comparative effectiveness of colorectal cancer screening
-
批准号:8849393
-
项目类别:
-
资助金额:$15.38万
-
财政年份:--
-
负责人:Karen J Wernli
-
依托单位:
Comparative effectiveness of colorectal cancer screening
-
批准号:8567517
-
项目类别:
-
资助金额:$12.74万
-
财政年份:--
-
负责人:Karen J Wernli
-
依托单位:
Comparative effectiveness of colorectal cancer screening
-
批准号:8686776
-
项目类别:
-
资助金额:$14.95万
-
财政年份:--
-
负责人:Karen J Wernli
-
依托单位:
国内基金
海外基金
流感病毒感染T淋巴细胞并致感染细胞异常死亡机制研究
-
批准号:81970010
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2019
-
负责人:曹彬
-
依托单位: